High rates of infection associated with the use of maintenance rituximab monotherapy in non-Hodgkin lymphoma

Internal Medicine Journal

Volumn 39, Issue 11, 2009, Pages 778-779

  Azad, A ^a   Campbell, P ^a  

^a GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RITUXIMAB;

AGE; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EARLY DIAGNOSIS; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL INFECTION; HERPES VIRUS; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RATE; INFECTION RISK; LETTER; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE THERAPY; MALE; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE;

EID: 71049140001     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02046.x     Document Type: Letter

References (5)

1. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 108 : 3295.
2. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005 16 : 1675 1682.
3. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005 31 : 456 473.
4. Goodman ER, Fiedor PS, Fein S, Athan E, Hardy MA. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg 1996 62 : 435 442.
5. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinaemia: a frequently unrecognised and easily treatable complication. Ann Oncol 2006 17 : 1424 1427.